Conatus Pharmaceuticals (CNAT) Reports In-Line Q1 EPS

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q1 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• L3Harris CEO steps down amid conduct review, shares drop